Novo Nordisk CFO On Metsera, Hims And Lilly, And Why 'Hyper Growth' Has Stalled

Group 1: Sales Outlook and Performance - Novo Nordisk has cut its sales outlook for the third time this year, now expecting sales growth of 8% to 11%, down from a previous guidance of 8% to 14% [1] - The company reported third-quarter sales of approximately $11.54 billion, which was below the forecast of $11.94 billion, despite a 5% year-over-year growth [2] - Wegovy, a weight-loss drug, generated about $3.13 billion in sales, growing nearly 18% but falling short of expectations of $3.33 billion [3] Group 2: Earnings and Market Reaction - Earnings per share for Novo Nordisk were approximately 69 cents, reflecting a 26% decline [2] - In premarket trading, Novo Nordisk's stock dipped 1.4% to $47.60 following the announcement of the revised sales outlook [4] Group 3: Product Performance - Ozempic, a diabetes treatment, brought in roughly $4.73 billion in sales, matching expectations and showing a 3% increase year over year [3] - CEO Mike Doustdar indicated that the lower growth expectations for GLP-1 treatments have led to the narrowing of the sales guidance [3]